Overview
Melanotan II is a synthetic cyclic heptapeptide analog of alpha-melanocyte-stimulating hormone (α-MSH), best known for its tanning effects via stimulation of melanogenesis. It is a shorter, more potent analog than Melanotan I (afamelanotide), composed of 7 amino acids and binding to multiple melanocortin receptors (MC1R, MC3R, MC4R, MC5R) — which accounts for its broader systemic profile.
Beyond pigmentation, research has noted MT-II's effects on libido (via MC4R, the same target as the FDA-approved bremelanotide / PT-141) and appetite suppression. Unlike Melanotan I, which is more selective for MC1R and is approved for clinical use as Scenesse for erythropoietic protoporphyria, Melanotan II remains a research-only compound and is not approved for human use in any jurisdiction. Side-effect profile (nausea, flushing, increased moles) is more pronounced than with MT-I due to its broader receptor activity.
Mechanism of action
Acts as a non-selective synthetic analog of alpha-melanocyte-stimulating hormone, agonizing MC1R (melanin production), MC3R/MC4R (libido and appetite), and MC5R.
Reported benefits
- ▸Promotes a natural-looking skin tan without excessive UV exposure
- ▸Provides photoprotective effects for individuals with light sensitivity
- ▸Assists in appetite regulation and fatty acid metabolism
- ▸May support cardiovascular health and blood pressure management
- ▸Potential neuroprotective properties and improved nerve recovery
Reported side effects
- ·Nausea
- ·Reduced appetite
- ·Headaches
- ·Skin pigmentation changes